Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Allison Berger"'
Autor:
Xiaoguang Wang, Canping Chen, Dan Vuong, Sonia Rodriguez-Rodriguez, Vi Lam, Carly Roleder, Jing H. Wang, Swetha Kambhampati, Allison Berger, Nathan Pennock, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Tanya Siddiqi, Lili Wang, Zheng Xia, Alexey V. Danilov
Publikováno v:
Leukemia.
Neddylation is a sequential enzyme-based process which regulates the function of E3 Cullin-RING ligase (CRL) and thus degradation of substrate proteins. Here we show that CD8+ T cells are a direct target for therapeutically relevant anti-lymphoma act
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Autor:
Todd M. Pitts, Alice McDonald, John J. Tentler, Aik Choon Tan, Kit Man Wong, Peter G Smith, Peter J. Klauck, Stacey M. Bagby, S. Gail Eckhardt, Anna Spreafico, Heather M. Selby, Stephen J. Blakemore, Allison Berger, Lindsey N. Micel
Publikováno v:
Investigational New Drugs. 35:11-25
Background The neddylation pathway conjugates NEDD8 to cullin-RING ligases and controls the proteasomal degradation of specific proteins involved in essential cell processes. Pevonedistat (MLN4924) is a selective small molecule targeting the NEDD8-ac
Autor:
Thea Kalebic, Neeraj Gupta, Lillian L. Siu, John S. Kauh, David Smith, Feng Gao, Ai Min Hui, Jeffrey R. Infante, Gordana Vlahovic, Allison Berger, Jianchang Lin, John A. Thompson, Deborah Berg, Guohui Liu, Stephen Tirrell, Daniel C. Sullivan, Alessandra Di Bacco
Publikováno v:
Investigational New Drugs
SummaryPurpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, i
Autor:
Thomas J. Waldschmidt, Michael R. Acevedo, Van S. Tompkins, Ramakrishna Sompallae, Kaylia Duncan, Alicia K. Olivier, Siegfried Janz, Herbert C. Morse, Guido Tricot, Lorraine T. Tygrett, Susan A. Walsh, Allison Berger, Laura L. Boles Ponto, John Sunderland, Fenghuang Zhan, Timothy R. Rosean
Publikováno v:
Blood Cancer Journal
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the